RecruitingNot applicableNCT07646847

A Study of a Side Effects and Resource Navigation Program for People With Cancer

The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.

Checked against the public recordLast updated Jul 31, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations8
SponsorMemorial Sloan Kettering Cancer Center
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Other: Immunotherapy CARE Program
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Documentation of Disease o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR) * Prior Treatment o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR) * Age ≥ 18 (per EMR) * Not Pregnant and Not Nursing (per self-report) * At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report) * Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report) * Can speak English or Spanish (per self-report) * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team) * Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
  • City College of New York (Data Collection AND Specimen Analysis)New York, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
  • Memorial Sloan Kettering Nassau (All protocol activities)Rockville Centre, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 31, 2026. Always confirm current availability with the study team.

View original record ↗